原发性硬化胆管炎的基于胆汁酸的疗法:当前的景观和未来的发展
Stefano Fiorucci1, Ginevra Urbani1, Cristina Di Giorgio1
1Dipartimento di Medicina e Chirurgia, Università di Perugia, 06123 Perugia, Italy.
Cells
|October 15, 2024
概括
初级硬化性胆道炎 (PSC) 是一种罕见的肝病,缺乏经批准的治疗方法. 新兴疗法针对胆酸通路,肠道微生物群和炎症,为患者提供了新的希望.
科学领域:
- 肝病学和胃肠道学
- 药物发现和开发 药物发现和开发
- 免疫学 免疫学 免疫学
背景情况:
- 初级硬化性脑膜炎 (PSC) 是一种罕见的慢性胆固醇性肝病,没有经批准的治疗方法.
- 乌尔索多西胆酸 (UDCA) 是常用的,但缺乏改善无移植生存的证据.
- PSC的发病过程涉及胆血管细胞和免疫失调.
研究的目的:
- 审查目前和新兴的PSC治疗策略.
- 突出针对PSC涉及的各种途径的新药候选药物.
- 强调针对胆酸代谢和肠道微生物群的重要性.
主要方法:
- 对PSC治疗药物的临床前和临床研究的审查.
- 药物类别的分析,包括FXR激动剂,FGF19类似物和PPAR激动剂.
- 针对GPBAR1 (TGR5),肠道微生物群和纤维化通路的药剂的探索.
主要成果:
- 几种药物类别正在调查中,其中FXR激动剂是最突出的.
- 向胆酸代谢,包括ASTB/IBAP抑制剂和FGF19类似物,是一个关键领域.
- 调节胆血管细胞上的GPBAR1 (TGR5) 和解决肠道失生症是有希望的途径.
结论:
- 一系列新的治疗药物正在开发中,用于PSC.
- 针对特定的分子通路和肠肝轴对未来的治疗有很大的前景.
- 进一步的研究对于确定这些新兴PSC疗法的疗效和安全性至关重要.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
Chronic Bowel Disorders: Introduction
397
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
397
Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
579
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
579


